[HTML][HTML] Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy
JR Lowe, DJ Perry, AKS Salama, CE Mathews… - … for ImmunoTherapy of …, 2016 - Springer
Background Checkpoint inhibitor immunotherapy is becoming an effective treatment
modality for an increasing number of malignancies. As a result, autoinflammatory side …
modality for an increasing number of malignancies. As a result, autoinflammatory side …
[PDF][PDF] Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy
JR Lowe, DJ Perry, AKS Salama, CE Mathews… - 2016 - researchgate.net
Background: Checkpoint inhibitor immunotherapy is becoming an effective treatment
modality for an increasing number of malignancies. As a result, autoinflammatory side …
modality for an increasing number of malignancies. As a result, autoinflammatory side …
[HTML][HTML] Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy
JR Lowe, DJ Perry, AKS Salama… - … for Immunotherapy of …, 2016 - ncbi.nlm.nih.gov
Background Checkpoint inhibitor immunotherapy is becoming an effective treatment
modality for an increasing number of malignancies. As a result, autoinflammatory side …
modality for an increasing number of malignancies. As a result, autoinflammatory side …
Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy
JR Lowe, DJ Perry, AKS Salama, CE Mathews… - … for ImmunoTherapy of …, 2016 - infona.pl
Background Checkpoint inhibitor immunotherapy is becoming an effective treatment
modality for an increasing number of malignancies. As a result, autoinflammatory side …
modality for an increasing number of malignancies. As a result, autoinflammatory side …
Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy
JR Lowe, DJ Perry, AKS Salama… - Journal for …, 2016 - pubmed.ncbi.nlm.nih.gov
Background Checkpoint inhibitor immunotherapy is becoming an effective treatment
modality for an increasing number of malignancies. As a result, autoinflammatory side …
modality for an increasing number of malignancies. As a result, autoinflammatory side …
[PDF][PDF] Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy
JR Lowe, DJ Perry, AKS Salama, CE Mathews… - 2016 - academia.edu
Background: Checkpoint inhibitor immunotherapy is becoming an effective treatment
modality for an increasing number of malignancies. As a result, autoinflammatory side …
modality for an increasing number of malignancies. As a result, autoinflammatory side …
Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy
JR Lowe, DJ Perry, AKS Salama… - … for ImmunoTherapy of …, 2016 - go.gale.com
Background Checkpoint inhibitor immunotherapy is becoming an effective treatment
modality for an increasing number of malignancies. As a result, autoinflammatory side …
modality for an increasing number of malignancies. As a result, autoinflammatory side …
Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy.
JR Lowe, DJ Perry, AK Salama… - … for Immunotherapy of …, 2016 - europepmc.org
Background Checkpoint inhibitor immunotherapy is becoming an effective treatment
modality for an increasing number of malignancies. As a result, autoinflammatory side …
modality for an increasing number of malignancies. As a result, autoinflammatory side …
[HTML][HTML] Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy
JR Lowe, DJ Perry, AKS Salama… - Journal for …, 2016 - jitc.biomedcentral.com
Checkpoint inhibitor immunotherapy is becoming an effective treatment modality for an
increasing number of malignancies. As a result, autoinflammatory side-effects are also being …
increasing number of malignancies. As a result, autoinflammatory side-effects are also being …
[引用][C] Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy
JR Lowe, DJ Perry, AKS Salama, CE Mathews… - … for ImmunoTherapy of …, 2016 - cir.nii.ac.jp
Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary
to combination ipilimumab and nivolumab immunotherapy | CiNii Research CiNii 国立情報学 …
to combination ipilimumab and nivolumab immunotherapy | CiNii Research CiNii 国立情報学 …